Compare GP & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GP | BIVI |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4M | 10.8M |
| IPO Year | 2020 | N/A |
| Metric | GP | BIVI |
|---|---|---|
| Price | $0.83 | $1.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 31.6K | ★ 74.6K |
| Earning Date | 02-13-2026 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,542,318.00 | N/A |
| Revenue This Year | $81.12 | N/A |
| Revenue Next Year | $91.69 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.76 | $1.16 |
| 52 Week High | $10.90 | $25.76 |
| Indicator | GP | BIVI |
|---|---|---|
| Relative Strength Index (RSI) | 27.58 | 27.36 |
| Support Level | $0.76 | $1.40 |
| Resistance Level | $0.86 | $1.46 |
| Average True Range (ATR) | 0.07 | 0.09 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 21.43 | 9.47 |
GreenPower Motor Co Inc is the manufacturer and distributor of all-electric charter, school, and city buses. The company offers electric-powered transit buses deploying electric drive and battery technologies with a lightweight chassis and low-floor body. Its product line includes all-electric transit buses, all-electric school buses, and shuttle buses. The company's buses depend on clean sheet design and utilize a custom battery management system and a proprietary flex power system for the drive motors. Geographically, the company generates a majority of its revenue from the United States of America and the rest from Canada.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.